PLIAGLIS Drug Patent Profile
✉ Email this page to a colleague
When do Pliaglis patents expire, and when can generic versions of Pliaglis launch?
Pliaglis is a drug marketed by Crescita Therap and is included in one NDA. There are three patents protecting this drug.
This drug has seven patent family members in seven countries.
The generic ingredient in PLIAGLIS is lidocaine; tetracaine. There are twenty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lidocaine; tetracaine profile page.
DrugPatentWatch® Generic Entry Outlook for Pliaglis
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 14, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PLIAGLIS?
- What are the global sales for PLIAGLIS?
- What is Average Wholesale Price for PLIAGLIS?
Summary for PLIAGLIS
| International Patents: | 7 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Clinical Trials: | 10 |
| Drug Prices: | Drug price information for PLIAGLIS |
| What excipients (inactive ingredients) are in PLIAGLIS? | PLIAGLIS excipients list |
| DailyMed Link: | PLIAGLIS at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for PLIAGLIS
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for PLIAGLIS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cutia Therapeutics（Wuxi）Co.,Ltd | Phase 3 |
| University of Michigan | Phase 4 |
| American Association of Endodontists | Phase 4 |
Pharmacology for PLIAGLIS
| Drug Class | Amide Local Anesthetic Antiarrhythmic Ester Local Anesthetic |
| Physiological Effect | Local Anesthesia |
US Patents and Regulatory Information for PLIAGLIS
PLIAGLIS is protected by three US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PLIAGLIS is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting PLIAGLIS
Solid-forming local anesthetic formulations for pain control
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Solid-forming local anesthetic formulations for pain control
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Solid-forming topical formulations for pain control
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PLIAGLIS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Crescita Therap | PLIAGLIS | lidocaine; tetracaine | CREAM;TOPICAL | 021717-001 | Jun 29, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PLIAGLIS
When does loss-of-exclusivity occur for PLIAGLIS?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 11205730
Patent: Solid-forming local anesthetic formulations for pain control
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2012017554
Patent: formulações de anestésicas locais formadoras de sólido para controle da dor
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 22220
Patent: FORMULATIONS POUR ANESTHESIE LOCALE SE SOLIDIFIANT POUR LA GESTION DE LA DOULEUR (SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL)
Estimated Expiration: ⤷ Sign Up
China
Patent: 2834096
Patent: Solid-forming local anesthetic formulations for pain control
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 23660
Patent: FORMULATIONS POUR ANESTHÉSIE LOCALE SE SOLIDIFIANT POUR LA GESTION DE LA DOULEUR (SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL)
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 12008168
Patent: FORMULACIONES ANESTESICAS LOCALES QUE FORMAN SOLIDOS PARA CONTROL DEL DOLOR. (SOLID-FORMING LOCAL ANESTHETIC FORMULATIONS FOR PAIN CONTROL.)
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering PLIAGLIS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 1376043 | ⤷ Sign Up | |
| Brazil | 112012017554 | formulações de anestésicas locais formadoras de sólido para controle da dor | ⤷ Sign Up |
| Spain | 2276697 | ⤷ Sign Up | |
| European Patent Office | 1278496 | ⤷ Sign Up | |
| China | 1332622 | ⤷ Sign Up | |
| European Patent Office | 1401408 | ⤷ Sign Up | |
| Australia | 6406299 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
